Prime Medicine, Inc.
PRME
NASDAQ·Healthcare·Biotechnology·Mkt cap $668.3M
$3.70
▼ -0.27%
P/E
-3.36
Mkt Cap
$668.3M
52-Wk Range
$2.67–$6.94
52-Week Range
$2.67 - $6.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 4.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced Prime Editing technology
- Proprietary gene modification methods
- Highly precise genetic intervention capabilities
- Strong intellectual property portfolio
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Expanding genetic medicine market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+25.0% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PRME right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 6, 2026
Reported EPS of -$0.24 vs -$0.26 consensus (+6.7% surprise). Revenue of $1.2M vs $2.3M expected (-48.7%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.7%
Revenue trend · last 8Q
—
—
+146%
—
+486%
-62%
-41%
+4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$209.0K
$2.2M
$1.5M
$1.1M
$1.2M
$838.0K
$856.0K
$1.2M
Margins · last 8Q
Gross
100.0%
Profit
-3649.0%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$8.00
▲ +116.2% vs $3.70
Latest: TD Cowen · Jul 8, 2026
1 analyst covering
vs Industry
How PRME stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related